Hunan Jiudian Pharmaceutical Co., Ltd. (SHE:300705)
12.94
+0.10 (0.78%)
Apr 29, 2026, 3:04 PM CST
SHE:300705 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,010 | 3,111 | 2,930 | 2,691 | 2,325 | 1,627 |
Other Revenue | - | - | 1.15 | 1.02 | 0.89 | 0.82 |
| 3,010 | 3,111 | 2,931 | 2,693 | 2,326 | 1,628 | |
Revenue Growth (YoY) | -0.85% | 6.15% | 8.85% | 15.75% | 42.92% | 66.40% |
Cost of Revenue | 855.11 | 841.68 | 790.88 | 621.79 | 522.52 | 365.47 |
Gross Profit | 2,155 | 2,269 | 2,140 | 2,071 | 1,804 | 1,262 |
Selling, General & Admin | 1,466 | 1,470 | 1,331 | 1,405 | 1,285 | 878.31 |
Research & Development | 189.5 | 218.41 | 245.97 | 254.12 | 201.26 | 146.26 |
Other Operating Expenses | -5.36 | -2.65 | 25.15 | 28.47 | 25.87 | 21.04 |
Operating Expenses | 1,650 | 1,686 | 1,598 | 1,696 | 1,525 | 1,051 |
Operating Income | 505.33 | 583.19 | 541.62 | 375.12 | 278.84 | 211.22 |
Interest Expense | -0.17 | - | -18.63 | -11.06 | -18.42 | -16.01 |
Interest & Investment Income | - | - | 8.56 | 7.67 | 6.8 | 5.82 |
Currency Exchange Gain (Loss) | - | - | -0.26 | -0.42 | -0.27 | -0.14 |
Other Non Operating Income (Expenses) | -28.56 | -25.07 | -0.58 | -0.29 | -0.24 | -0.19 |
EBT Excluding Unusual Items | 476.61 | 558.12 | 530.71 | 371.02 | 266.71 | 200.7 |
Gain (Loss) on Sale of Investments | -1.4 | -0.96 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.05 | 0.05 | - | 0.03 | - | 0.02 |
Asset Writedown | -31 | -30.85 | -1.92 | -1.46 | -1.3 | -1.9 |
Other Unusual Items | - | - | 43.4 | 32.57 | 24.81 | 27.38 |
Pretax Income | 444.26 | 526.36 | 572.19 | 402.16 | 290.22 | 226.19 |
Income Tax Expense | 45.73 | 56.33 | 59.82 | 33.9 | 20.52 | 21.94 |
Earnings From Continuing Operations | 398.52 | 470.04 | 512.38 | 368.26 | 269.7 | 204.25 |
Minority Interest in Earnings | 5.26 | 2.78 | - | - | - | - |
Net Income | 403.78 | 472.82 | 512.38 | 368.26 | 269.7 | 204.25 |
Net Income to Common | 403.78 | 472.82 | 512.38 | 368.26 | 269.7 | 204.25 |
Net Income Growth | -21.21% | -7.72% | 39.13% | 36.55% | 32.05% | 148.29% |
Shares Outstanding (Basic) | 496 | 493 | 488 | 478 | 460 | 461 |
Shares Outstanding (Diluted) | 501 | 498 | 493 | 504 | 460 | 461 |
Shares Change (YoY) | 0.93% | 1.02% | -2.34% | 9.55% | -0.15% | 0.13% |
EPS (Basic) | 0.81 | 0.96 | 1.05 | 0.77 | 0.59 | 0.44 |
EPS (Diluted) | 0.81 | 0.95 | 1.04 | 0.73 | 0.59 | 0.44 |
EPS Growth | -21.94% | -8.65% | 42.47% | 24.64% | 32.24% | 147.98% |
Free Cash Flow | -64.97 | -5.83 | 348.5 | 4.37 | -144.39 | 64.94 |
Free Cash Flow Per Share | -0.13 | -0.01 | 0.71 | 0.01 | -0.31 | 0.14 |
Dividend Per Share | - | - | 0.313 | 0.229 | 0.169 | 0.133 |
Dividend Growth | - | - | 36.49% | 36.00% | 26.67% | 507.76% |
Gross Margin | 71.59% | 72.94% | 73.01% | 76.91% | 77.54% | 77.55% |
Operating Margin | 16.79% | 18.75% | 18.48% | 13.93% | 11.99% | 12.98% |
Profit Margin | 13.41% | 15.20% | 17.48% | 13.68% | 11.59% | 12.55% |
Free Cash Flow Margin | -2.16% | -0.19% | 11.89% | 0.16% | -6.21% | 3.99% |
EBITDA | 637.45 | 707.33 | 633.88 | 446.5 | 338.49 | 264.8 |
EBITDA Margin | 21.18% | 22.74% | 21.63% | 16.58% | 14.55% | 16.27% |
D&A For EBITDA | 132.11 | 124.14 | 92.26 | 71.37 | 59.64 | 53.58 |
EBIT | 505.33 | 583.19 | 541.62 | 375.12 | 278.84 | 211.22 |
EBIT Margin | 16.79% | 18.75% | 18.48% | 13.93% | 11.99% | 12.98% |
Effective Tax Rate | 10.29% | 10.70% | 10.45% | 8.43% | 7.07% | 9.70% |
Revenue as Reported | - | - | 2,931 | 2,693 | 2,326 | 1,628 |
Advertising Expenses | - | - | 79.64 | 73.01 | 77.41 | 28.51 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.